Neuphoria Therapeutics (NEUP) EV to CFO (2023 - 2026)

Neuphoria Therapeutics (NEUP) has reported EV to CFO for 4 consecutive years, with 144.81 the latest figure, recorded in Q1 2026.

• On a quarterly basis, EV to CFO fell 336.59% year-over-year to 144.81 in Q1 2026; TTM through Mar 2026 was 28.43, a 102.64% decrease from a year earlier, with the FY2025 full-year figure at 8653.28, up 11370.36% from the prior year.
• EV to CFO was 144.81 for Q1 2026 at Neuphoria Therapeutics, down from 71.75 in the prior quarter.
• Over five years, EV to CFO peaked at 61.2 in Q1 2025 and troughed at 909.95 in Q3 2023.
• A 4-year average of 305.98 and a median of 244.45 in 2025 frame the typical range for EV to CFO.
• Across the five-year window, EV to CFO surged 113.16% in 2025 and sank 336.59% in 2026, its largest moves.
• Over 4 years, EV to CFO stood at 558.62 in 2023, then surged by 77.44% to 126.04 in 2024, then surged by 43.07% to 71.75 in 2025, then tumbled by 101.81% to 144.81 in 2026.
• The last three EV to CFO figures came in at 144.81 (Q1 2026), 71.75 (Q4 2025), and 383.17 (Q3 2025), per Business Quant data.